New technologies fuel advancements in digital health

Production of monoclonal antibodies (mAbs) therapies has traditionally been expensive and complicated. Scaling up from discovery to lab scale and then to commercial manufacturing can be streamlined by using a consistent approach. We speak to Dr Hani El-Sabbahy, Advanced Application Engineering Specialist from 3M, to understand more about overcoming problems with scalability and reliability of clarification solutions.